Status:
COMPLETED
Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation
Lead Sponsor:
University Hospital Carl Gustav Carus
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
Efforts to decrease the risk of GvHD by depleting T cells from the graft in CML patients have been complicated by an increased incidence of leukemia-relapse. Newer protocols using CD34+ selected hemat...
Detailed Description
The conditioning protocol contains: Total Body Irradiation 8-12 Gy (4-6 x 2 Gy, a 2 x/die) day -9 to-7 Thiotepa 10 mg/kg (2 x 5 mg/kg) day -5 Fludarabine 200 mg/m2 (5 x 40 mg/m2) day -6 to-2 ATG Fres...
Eligibility Criteria
Inclusion
- age 18-60
- Ph+ CML
- HLA A0201, 0301, 1101, B0801
- BCR-ABL b3a2 positive
- no significant comorbidities
- resistance or intolerance of imatinib
Exclusion
- HIV positive
- blast crisis
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00460629
Start Date
March 1 2005
Last Update
June 20 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Klinik und Poliklinik I
Dresden, Germany, 01307